Evidence map›Paper›PMID 42268404›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [

Ann-Christin Eder, Christoph-Ferdinand Wielenberg, Mohamed Aymen Omrane, Aikaterini Klotsotyra, Katia Brüggemann, Mohamed El Fakiri, Heiko Becker, Michael Quante, Michael Mix, Matthias Eder and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ann-Christin Eder *Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Christoph-Ferdinand Wielenberg *Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Mohamed Aymen OmraneDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Aikaterini KlotsotyraDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Katia BrüggemannDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Mohamed El FakiriDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Heiko BeckerDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, University of Freiburg, Freiburg, Germany.
Michael QuanteDepartment of Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany.
Michael MixDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Matthias EderDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Philipp T MeyerDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Martin T FreitagDepartment of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. mtfreitag@gmail.com.ORCID 0000-0002-2116-6873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeErythropoietin-producing hepatocellular receptor A2 (EphA2) is overexpressed in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), in which it correlates with poor prognosis. Although EphA2 is considered a promising target receptor for theranostic applications, suitable radiotracers for clinical imaging have been lacking. This study reports first clinical experiences with [

methodsSeven patients with histologically confirmed PDAC (5 after chemotherapy, 2 at initial staging) underwent PET/CT imaging. Four were scanned at 15, 30, 45, 60 and 180 min. and three at 45 min. after injection of [

resultsNo adverse events were observed. The kidneys received the highest absorbed dose (0.31 ± 0.02 mGy/MBq), while the effective dose was 0.017 ± 0.002 mSv/MBq. [

conclusionsOur initial clinical experiences demonstrate that [

Indexed as

Gallium RadioisotopesPancreatic NeoplasmsPeptides, CyclicPositron Emission Tomography Computed TomographyReceptor, EphA2AgedFemaleHumansMaleMiddle AgedPositron-Emission TomographyRadiometryRadiopharmaceuticalsTissue DistributionEPHA2 protein, humanGallium-68Gallium RadioisotopesPeptides, CyclicRadiopharmaceuticalsReceptor, EphA2Bicyclic peptideEphA2Pan-cancer agentPDACPETTumor targeting

Identifiers

PMID42268404
PMCPMC13525963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.